评估母亲病毒载量对围产期和产后HIV传播的影响:系统综述与荟萃分析
该系统综述与荟萃分析检索1989年至2024年文献,纳入147项研究、82 723对母婴,按母亲HIV病毒载量(mHVL)分层估算围产期和产后传播风险。mHVL<50拷贝/mL时围产期传播合并风险为0.2%,产后月传播风险为0.1%;在孕前接受抗逆转录病毒治疗且近分娩mHVL<50拷贝/mL的4675名女性中围产期传播为零。作者认为数据支持孕期和分娩时U=U,但母乳喂养期间U=U证据不足。
要点
- mHVL<50拷贝/mL时围产期传播合并风险为0.2%(95%CI 0.2-0.3)。
- 孕前接受ART且近分娩mHVL<50拷贝/mL的4675名女性中围产期传播为零(0%,95%CI 0.0-0.1)。
- 近期mHVL<50拷贝/mL时产后月传播风险为0.1%(95%CI 0.0-0.4),作者指出非常低但非零。
核心结论
- mHVL<50拷贝/mL时围产期传播总体≤0.2%。
- 孕前接受ART且近分娩mHVL<50拷贝/mL的女性中观察到零传播,支持孕期和分娩时U=U。
- 近期mHVL<50拷贝/mL的女性中产后传播非常低但非零。
- 现有数据多来自缺乏频繁mHVL监测或现代一线ART方案的研究,不足以评估母乳喂养期间U=U。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase、Web of Science、Cochrane Library、CINAHL、WHO全球健康图书馆及IAS和CROI会议摘要(2016-24),纳入1989年1月1日至2024年12月31日发表的研究。
- 共纳入147项研究,其中138项贡献围产期分析、13项贡献产后分析,所有分析合计82 723对母婴。
- 按预设mHVL分类合并围产期和产后传播风险,并使用泊松荟萃回归进行校正相对风险(aRR)比较分析。
- 方案在PROSPERO注册(CRD42019146768)。
主要发现
- 围产期传播合并风险:mHVL<50拷贝/mL为0.2%(95%CI 0.2-0.3),50-999拷贝/mL为1.3%(95%CI 1.0-1.7),≥1000拷贝/mL为5.1%(95%CI 2.6-7.9)。
- 围产期传播aRR:mHVL 50-999拷贝/mL vs <50拷贝/mL为6.3(95%CI 3.9-10.3),≥1000拷贝/mL vs <50拷贝/mL为22.5(95%CI 13.9-36.5)。
- 亚组分析:5项研究报告4675名孕前接受ART且近分娩mHVL<50拷贝/mL的女性,围产期传播为零(0%,95%CI 0.0-0.1)。
- 产后月传播风险:近期mHVL<50拷贝/mL为0.1%(95%CI 0.0-0.4),mHVL≥50拷贝/mL为0.5%(95%CI 0.1-1.8)。
临床怎么用
- 作者认为孕前接受ART且近分娩mHVL<50拷贝/mL的女性中零围产期传播支持孕期和分娩时U=U。
- 作者指出近期mHVL<50拷贝/mL的女性中产后传播非常低但非零。
- 作者指出现有数据不足以评估母乳喂养期间U=U。
局限性
- 现有数据多来自缺乏频繁mHVL监测或现代一线ART方案的研究,不足以评估母乳喂养期间U=U。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although a growing body of evidence supports zero risk of sexual HIV transmission from a person with sustained virological suppression, known as U=U (undetectable equals untransmittable), data have been insufficient to determine whether this is also true for vertical HIV transmission. We conducted a systematic review and meta-analysis to quantify vertical transmission risk by maternal HIV viral load (mHVL) and to evaluate the applicability of U=U to perinatal and postnatal HIV transmission. METHODS: In this systematic review and meta-analysis, we searched PubMed, Embase, Web of Science, Cochrane Library, Cumulative Index of Nursing and Allied Health Literature, the WHO Global Health Library, and abstracts from the International AIDS Society Conference and the Conference on Retroviruses and Opportunistic Infections (2016-24) for studies published from Jan 1, 1989, to Dec 31, 2024, reporting the relationship between mHVL near birth (to estimate perinatal transmission risk by 6 weeks) or during breastfeeding (to estimate monthly postnatal transmission risk by mHVL within the past 6 months) and vertical transmission. We pooled risks of perinatal and postnatal transmission across prespecified mHVL categories. We also conducted comparative analyses to determine the adjusted relative risk (aRR) of transmission by mHVL using Poisson meta-regression. The protocol for this analysis is registered on the International Prospective Register of Systematic Reviews (PROSPERO; CRD42019146768). FINDINGS: 147 studies were included in the analysis; 138 studies contributed to perinatal analyses and 13 studies contributed to postnatal analyses. Data on 82 723 mother-child pairs were included across all analyses. Pooled perinatal transmission risks were 0·2% (95% CI 0·2-0·3) with a mHVL of <50 copies per mL, 1·3% (1·0-1·7) with 50-999 copies per mL, and 5·1% (2·6-7·9) with ≥1000 copies per mL. aRRs of perinatal transmission were 6·3 (3·9-10·3) with a mHVL of 50-999 copies per mL and 22·5 (13·9-36·5) with ≥1000 copies per mL versus <50 copies per mL. In subgroup analyses, in five studies reporting on 4675 women receiving pre-conception antiretroviral therapy (ART) with a mHVL of <50 copies per mL near birth, there were zero (0%, 0·0-0·1) perinatal transmissions. Monthly postnatal transmission risks were 0·1% (0·0-0·4) with recent mHVL <50 copies per mL and 0·5% (0·1-1·8) with a mHVL of ≥50 copies per mL. INTERPRETATION: Perinatal transmission with a mHVL of <50 copies per mL is ≤0·2% overall. Zero transmissions were observed among women receiving ART before pregnancy with a mHVL of <50 copies per mL near birth, supporting U=U in pregnancy and birth. Postnatal transmission was very low-but not zero-among women with a recent mHVL of <50 copies per mL. Current data, largely from studies lacking frequent mHVL monitoring or modern first-line ART regimens, are insufficient to assess U=U during breastfeeding. FUNDING: National Institutes of Health, WHO, and Massachusetts General Hospital.
引用
- Dugdale CM, Ufio O, Giardina J, et al. Estimating the effect of maternal viral load on perinatal and postnatal HIV transmission: a systematic review and meta-analysis. Lancet. 2025. PMID: 40652949. doi:10.1016/S0140-6736(25)00765-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。